WT1 and Bcl2 expression in melanocytic lesions of the conjunctiva: An immunohistochemical study of 123 cases

Archives of Ophthalmology

Volumn 127, Issue 8, 2009, Pages 964-969

  Furusato, Emiko ^a   Hidayat, Ahmed A ^a   Man, Yan Gao ^a   Auerbach, Aaron ^a   Furusato, Bungo ^a   Rushing, Elisabeth J ^a  

^a ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 2; WT1 PROTEIN;

ANTIBODY LABELING; ARTICLE; CONJUNCTIVA; CONJUNCTIVA TUMOR; DIAGNOSTIC VALUE; DYSPLASTIC NEVUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MELANOCYTE; MELANOMA; MELANOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CHILD; CHILD, PRESCHOOL; CONJUNCTIVAL DISEASES; CONJUNCTIVAL NEOPLASMS; DYSPLASTIC NEVUS SYNDROME; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MELANOMA; MELANOSIS; MIDDLE AGED; NEOPLASM PROTEINS; NEVUS, PIGMENTED; PROTO-ONCOGENE PROTEINS C-BCL-2; S100 PROTEINS; TUMOR MARKERS, BIOLOGICAL; WT1 PROTEINS; YOUNG ADULT;

EID: 68549121122     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2009.183     Document Type: Article

References (32)

1. Burwell EA, McCarty GP, Simpson LA, Thompson KA, Loeb DM. Isoforms of the Wilms' tumor suppressor gene (WT1) have distinct effects on mammary epithelial cells. Oncogene. 2007;26(23):3423-3430.
2. Hohenstein P, Hastie ND. The many facets of the Wilms' tumour gene, WT1. Hum Mol Genet. 2006;15(Spec No. 2):R196-R201.
3. Rodeck U, Bossler A, Kari C, et al. Expression of the WT1 Wilms tumor gene by normal and malignant human melanocytes. Int J Cancer. 1994;59(1):78-82.
4. Wagner N, Wagner K-D, Schley G, et al. The Wilms' tumor suppressor Wt1 is associated with the differentiation of retinoblastoma cells. Cell Growth Differ. 2002;13(7):297-305.
5. Nakatsuka S, Oji Y, Horiuchi T, et al. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol. 2006;19(6):804-814.
6. Wilsher M, Cheerala B. WT1 as a complementary marker of malignant melanoma: an immunohistochemical study of whole sections. Histopathology. 2007;51(5):605-610.
7. Wagner N, Panelos J, Massi D, Wagner K-D. The Wilms' tumor suppressor WT1 is associated with melanoma proliferation. Pflugers Arch. 2008;455(5):839-847.
8. Hockenbery D, Nuñez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 1990;348(6299):334-336.
9. Vaux DL, Cory S, Adams JM. Bcl2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988;335(6189):440-442.
10. Nuñez G, London L, Hockenbery D, Alexander M, McKearn JP, Korsmeyer SJ. Deregulated Bcl2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol. 1990;144(9):3602-3610.
11. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of Bcl2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci U S A. 1986;83(14):5214-5218.
12. Weiss LM, Warnke RA, Sklar J, Cleary ML. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med. 1987;317(19):1185-1189.
13. Yunis JJ, Oken MM, Kaplan ME, Ensrud KM, Howe RR, Theologides A. Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma. N Engl J Med. 1982;307(20):1231-1236.
14. Pezzella F, Turley H, Kuzu I, et al. Bcl2 protein in non-small-cell lung carcinoma. N Engl J Med. 1993;329(10):690-694.
15. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene Bcl2 in the prostate and its association with emergence of androgenin-dependent prostate cancer. Cancer Res. 1992;52(24):6940-6944.
16. van den Oord JJ, Vandeghinste N, De Ley M, De Wolf-Peeters C. Bcl2 expression in human melanocytes and melanocytic tumors. Am J Pathol. 1994;145(2):294-300.
17. Saenz-Santamaría MC, Reed JA, McNutt NS, Shea CR. Immunohistochemical expression of BCL2 in melanomas and intradermal nevi. J Cutan Pathol. 1994;21(5):393-397.
18. Cerroni L, Soyer HP, Kerl H. Bcl2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi. Am J Dermatopathol. 1995;17(1):7-11.
19. Ramsay JA, From L, Kahn HJ. Bcl2 protein expression in melanocytic neoplasms of the skin. Mod Pathol. 1995;8(2):150-154.
20. Tron VA, Krajewski S, Klein-Parker H, Li G, Ho VC, Reed JC. Immunohistochemical analysis of Bcl2 protein regulation in cutaneous melanoma. Am J Pathol. 1995;146(3):643-650.
21. Morales-Ducret CRJ, van de Rijn M, Smoller BR. Bcl2 expression in melanocytic nevi: insights into the biology of dermal maturation. Arch Dermatol. 1995;131(8):915-918.
22. Hussein MR. Analysis of Bcl2 protein expression in choroidal melanomas. J Clin Pathol. 2005;58(5):486-489.
23. Jay V, Yi Q, Hunter WS, Zielenska M. Expression of Bcl2 in uveal malignant melanoma. Arch Pathol Lab Med. 1996;120(5):497-498.
24. Chana JS, Wilson GD, Cree IA, et al. c-myc, p53, and Bcl2 expression and clinical outcome in uveal melanoma. Br J Ophthalmol. 1999;83(1):110-114.
25. Shields CL, Demirci H, Karatza E, Shields JA. Clinical survey of 1643 melanocytic and nonmelanocytic conjunctival tumors. Ophthalmology. 2004;111(9):1747-1754.
26. Shields CL, Fasiuddin AF, Mashayekhi A, Shields JA. Conjunctival nevi: clinical features and natural course in 410 consecutive patients. Arch Ophthalmol. 2004;122(2):167-175.
27. Folberg R, McLean IW, Zimmerman LE. Primary acquired melanosis of the conjunctiva. Hum Pathol. 1985;16(2):129-135.
28. Shields JA, Shields CL, Mashayekhi A, et al. Primary acquired melanosis of the conjunctiva: risks for progression to melanoma in 311 eyes. Ophthalmology. 2008;115(3):511-519.
29. Margo CE, Roper DL, Hidayat AA. Borderline melanocytic tumor of the conjunctiva: diagnostic and therapeutic considerations. J Pediatr Ophthalmol Strabismus. 1991;28(5):268-270.
30. Steuhl KP, Rohrbach JM, Knorr M, Thiel HJ. Significance, specificity, and ultrastructural localization of HMB45 antigen in pigmented ocular tumors. Ophthalmology. 1993;100(2):208-215.
31. Sharara NA, Alexander RA, Luthert PJ, Hungerford JL, Cree IA. Differential immunoreactivity of melanocytic lesions of the conjunctiva. Histopathology. 2001;39(4):426-431.
32. McDonnell JM, Sun YY, Wagner D. HMB45 immunohistochemical staining of conjunctival melanocytic lesions. Ophthalmology. 1991;98(4):453-458.